Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANRO 
Alto Neuroscience, Inc. (ANRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: ANRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11
1 Year Target Price $11
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.31% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 164.63M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 1.60 - 14.85 | Updated Date 10/19/2025 |
52 Weeks Range 1.60 - 14.85 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.72% | Return on Equity (TTM) -42.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -868067 | Price to Sales(TTM) - |
Enterprise Value -868067 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 27076629 | Shares Floating 15894523 |
Shares Outstanding 27076629 | Shares Floating 15894523 | ||
Percent Insiders 7.48 | Percent Institutions 71.39 |
Upturn AI SWOT
Alto Neuroscience, Inc.
Company Overview
History and Background
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized and highly effective treatments for mental health conditions. Founded with the aim of leveraging neurobiology to improve drug development for mental illnesses, Alto uses its platform to identify patient populations most likely to respond to its therapies.
Core Business Areas
- Drug Development: Focuses on developing novel therapeutics for various mental health conditions, including depression, PTSD, and cognitive impairment.
- Precision Psychiatry Platform: Utilizes brain biomarkers and other data to identify patient subgroups most likely to benefit from specific treatments.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
Alto Neuroscience is led by a team of experienced pharmaceutical executives and scientists. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- ALTO-100 (Depression): ALTO-100 is the company's lead drug candidate in clinical development for major depressive disorder (MDD). It is designed to target specific neurobiological pathways associated with depression. Market share data is not yet available as the product is in clinical trials. Competitors include pharmaceutical companies developing antidepressants such as Eli Lilly (LLY) and Pfizer (PFE).
- ALTO-202 (PTSD): ALTO-202 is being developed for post-traumatic stress disorder (PTSD). It targets specific brain circuits associated with fear and anxiety. Market share data unavailable, as it is in clinical trials. Competitors in the PTSD space include companies developing therapies for anxiety and trauma, like AbbVie (ABBV).
- ALTO-300 (Cognitive Impairment): ALTO-300 targets cognitive impairment in mental health disorders. Market share data unavailable, as it is in clinical trials. Key competitors in the cognitive impairment space include companies focusing on neurodegenerative diseases like Biogen (BIIB) and Eisai (ESAI).
Market Dynamics
Industry Overview
The mental health therapeutics market is large and growing, driven by increasing awareness and prevalence of mental health conditions. There is a significant unmet need for more effective and personalized treatments.
Positioning
Alto Neuroscience is positioned as a precision psychiatry company using biomarkers to improve treatment outcomes, differentiating it from traditional pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for mental health therapeutics is estimated to be in the tens of billions of dollars annually. Alto Neuroscience aims to capture a significant share of this market through its personalized medicine approach.
Upturn SWOT Analysis
Strengths
- Precision psychiatry platform
- Experienced leadership team
- Strong pipeline of drug candidates
- Focus on unmet medical needs
Weaknesses
- Early-stage company
- High R&D expenses
- Dependence on clinical trial success
- Limited commercial infrastructure
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing adoption of precision medicine
- Regulatory support for innovative therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Pricing pressures
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- BIIB
- ESAI
Competitive Landscape
Alto Neuroscience differentiates itself with its precision psychiatry platform, while competitors often have broader portfolios and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the expansion of the drug pipeline and advancement of clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates are not readily available due to the company's stage.
Recent Initiatives: Recent initiatives include advancing clinical trials for ALTO-100, ALTO-202, and ALTO-300, as well as expanding the precision psychiatry platform.
Summary
Alto Neuroscience is an early-stage biopharmaceutical company with a promising precision psychiatry platform. Its success hinges on the outcomes of its clinical trials. The company's focus on personalized mental health treatments positions it well in a growing market, but it faces significant risks associated with drug development and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are based on available information and may not be precise. The AI-based rating is based on available information and may not be a perfect indicator of future performance. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alto Neuroscience, Inc.
Exchange NYSE | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2024-02-02 | Founder, Chairman of the Board, CEO & President Dr. Amit Etkin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 76 | Website https://www.altoneuroscience.com |
Full time employees 76 | Website https://www.altoneuroscience.com | ||
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.